Drug Trial Radar · NCT04557462
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Sep 20, 2021
Primary completion
Dec 4, 2030
Study completion Dec 4, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safety and tolerability data for the investigational drug. Furthermore efficacy assessments conducted every 6 months will afford the opportunity to evaluate the clinical effects of iptacopan on long-term disease progression.
Conditions
- Primary IgA Nephropathy
Interventions
LNP023Drug
Capsule 200 mg (b.i.d.) taken orally twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and percentage of participants with serious adverse eventTime frame: Date of first administration of (Day 1) to 7 days after the date of the last actual administration of study treatment
- Number and percentage of participants with adverse eventTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
- Number and percentage of participants with adverse events of special interestTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual adminstration of study treatment
- Number and percentage of participants with abnormalities in vital signsTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
- Number and percentage of participants with abnormalities in ECGTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
- Number and percentage of participants with abnormalities in clinical laboratory evaluationsTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
Locations
161 sites in 36 countries. Site status is shown where the registry gives one.
AZ Kidney Dise and Hypertension Ctr
Glendale, Arizona · Active not recruiting
Kaiser Permanente
San Diego, California · Active not recruiting
North America Research Institute
San Dimas, California · Active not recruiting
University of Colorado Anschutz
Aurora, Colorado · Active not recruiting
Nephrology Associates PA
Newark, Delaware · Withdrawn
CaRe Research
Chubbuck, Idaho · Active not recruiting
Nep Assoc of Northern Illinois
Hinsdale, Illinois · Active not recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Active not recruiting
Brigham and Womens Hosp Harvard Med School
Boston, Massachusetts · Completed
Mayo Clinic Rochester
Rochester, Minnesota · Active not recruiting
Clin Rsrch Consult a JCCT Company
Kansas City, Missouri · Completed
DaVita Clinical Research
Las Vegas, Nevada · Active not recruiting
New Jersey Kidney Care
Jersey City, New Jersey · Active not recruiting
Col Uni Med Center New York Presby
New York, New York · Recruiting
Dallas Renal Group
Dallas, Texas · Active not recruiting
Prolato Clinical Research Center
Houston, Texas · Withdrawn
Novartis Investigative Site
CABA, Argentina · Active not recruiting
Novartis Investigative Site
CABA, Argentina · Active not recruiting
Novartis Investigative Site
Santa Fe, Argentina · Active not recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina · Active not recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina · Active not recruiting
Novartis Investigative Site
Woolloongabba, Queensland, Australia · Active not recruiting
Novartis Investigative Site
Adelaide, South Australia, Australia · Active not recruiting
Novartis Investigative Site
Parkville, Victoria, Australia · Active not recruiting
Novartis Investigative Site
Edegem, Belgium · Active not recruiting
Novartis Investigative Site
Leuven, Belgium · Active not recruiting
Novartis Investigative Site
Roeselare, West Vlaanderen, Belgium · Active not recruiting
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil · Active not recruiting
Novartis Investigative Site
Curitiba, Paraná, Brazil · Active not recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting
Novartis Investigative Site
São José do Rio Preto, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
Oshawa, Ontario, Canada · Withdrawn
Novartis Investigative Site
Temuco, Chile · Active not recruiting
Novartis Investigative Site
Beijing, China · Active not recruiting
Novartis Investigative Site
Guangzhou, China · Active not recruiting
Novartis Investigative Site
Ningbo, China · Active not recruiting
Novartis Investigative Site
Qingdao, China · Active not recruiting
Novartis Investigative Site
Shanghai, China · Active not recruiting
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.